Twist Bioscience (NASDAQ:TWST – Get Free Report) had its price objective dropped by investment analysts at TD Cowen from $190.00 to $137.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen‘s target price would indicate a potential upside of 24.71% from the stock’s previous close.
Several other brokerages have also recently commented on TWST. Robert W. Baird decreased their target price on Twist Bioscience from $187.00 to $135.00 and set an “outperform” rating for the company in a research report on Friday. BWS Financial reissued a “sell” rating and set a $45.00 price target on shares of Twist Bioscience in a research report on Friday, September 18th. Piper Sandler increased their price objective on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Finally, Guggenheim raised their price objective on Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $145.00.
View Our Latest Research Report on Twist Bioscience
Twist Bioscience Trading Down 3.8%
Twist Bioscience stock traded down $4.37 during midday trading on Friday, reaching $109.85. The stock had a trading volume of 318,673 shares, compared to its average volume of 1,781,233. The firm’s fifty day simple moving average is $150.57 and its two-hundred day simple moving average is $92.73. Twist Bioscience has a twelve month low of $23.30 and a twelve month high of $219.71. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The firm has a market cap of $6.89 billion, a price-to-earnings ratio of -49.83 and a beta of 2.25.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.07. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm had revenue of $126.64 million for the quarter, compared to analysts’ expectations of $123.55 million. Twist Bioscience’s revenue was up 26.7% on a year-over-year basis. Equities analysts anticipate that Twist Bioscience will post -2.11 EPS for the current fiscal year.
Insider Buying and Selling
In other news, CEO Emily Leproust sold 4,573 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total value of $619,184.20. Following the transaction, the chief executive officer directly owned 558,187 shares of the company’s stock, valued at approximately $75,578,519.80. This represents a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Dennis Cho sold 949 shares of the company’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total transaction of $128,494.60. Following the completion of the transaction, the insider directly owned 62,840 shares in the company, valued at $8,508,536. This trade represents a 1.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 495,279 shares of company stock worth $80,489,387. Insiders own 3.08% of the company’s stock.
Institutional Trading of Twist Bioscience
Institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Twist Bioscience in the second quarter valued at about $600,191,000. William Blair Investment Management LLC purchased a new stake in shares of Twist Bioscience during the 2nd quarter worth about $223,722,000. Bank of America Corp DE purchased a new stake in shares of Twist Bioscience during the 2nd quarter worth about $94,922,000. Stephens Investment Management Group LLC raised its stake in shares of Twist Bioscience by 1.7% during the 3rd quarter. Stephens Investment Management Group LLC now owns 780,419 shares of the company’s stock worth $150,808,000 after purchasing an additional 13,055 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new stake in shares of Twist Bioscience during the 1st quarter valued at about $22,563,000.
More Twist Bioscience News
These are some of the TWST news items that stood out recently:
- Positive Sentiment: Fiscal Q4 revenue was $126.6 million, up about 28% year over year and above expectations; the loss of $0.32 per share was also narrower than the cited consensus estimate. Article: Twist Bioscience Reports Q4 Loss, Beats Revenue Estimates
- Positive Sentiment: Q1 fiscal 2027 revenue guidance of $130 million–$132 million tops the $126.3 million consensus, offering a near-term sign of continued growth. Article: Twist Bioscience Earnings Results
- Negative Sentiment: Robert W. Baird cut its price target from $187 to $135, while maintaining an Outperform rating. The target reduction may signal more cautious expectations, even though it remains above the cited share price. Article: Baird Lowers Twist Bioscience Price Target
About Twist Bioscience
Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.
Further Reading
- Five stocks we like better than Twist Bioscience
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
